Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease

• Published in: Neurology Vol. 65; no. 9; p. 1402
• Main Authors: Irizarry, M C, Gurol, M E, Raju, S, Diaz-Arrastia, R, Locascio, J J, Tennis, M, Hyman, B T, Growdon, J H, Greenberg, S M, Bottiglieri, T
• Format: Journal Article
• Language: English
• Published: United States 08.11.2005
• Subjects: Aged; Aged, 80 and over; Aging - blood; Aging - metabolism; Alzheimer Disease - blood; Alzheimer Disease - physiopathology; Amyloid beta-Peptides - blood; Brain - metabolism; Brain - physiopathology; Causality; Cerebral Amyloid Angiopathy - blood; Cerebral Amyloid Angiopathy - physiopathology; Cognition Disorders - blood; Cognition Disorders - physiopathology; Creatinine - blood; Female; Folic Acid - blood; Homocysteine - blood; Humans; Levodopa - pharmacology; Male; Memory Disorders - blood; Memory Disorders - physiopathology; Middle Aged; Neurodegenerative Diseases - blood; Neurodegenerative Diseases - physiopathology; Parkinson Disease - blood; Parkinson Disease - physiopathology; Predictive Value of Tests; Vitamin B 12 - blood
• ISSN: 1526-632X
• DOI: 10.1212/01.wnl.0000183063.99107.5c

Elevated plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease and is reported to be an independent risk factor for Alzheimer disease (AD) and cognitive decline. tHcy may potentiate neurotoxic and vasculopathic processes, including amyloid beta protein (Abeta) metabolism, implicated in neurodegenerative diseases. To examine the relationship of plasma total tHcy levels with clinical, demographic, biochemical, and genetic factors in aging, mild cognitive impairment (MCI), AD, cerebral amyloid angiopathy (CAA), and Parkinson disease (PD). Plasma tHcy, folate, vitamin B(12), creatinine, and Abeta levels were assessed in individuals evaluated in the Memory, Stroke, and Movement Disorders Units of Massachusetts General Hospital with diagnoses of AD (n = 145), MCI (n = 47), PD (n = 93), CAA (67), hypertensive intracerebral hemorrhage (hICH) (n = 25), and no dementia (n = 88). The tHcy levels did not differ across AD, MCI, CAA, hICH, and nondemented control subjects but were increased in the PD group (p < 0.01). The elevated levels within the PD group were due to high tHcy in individuals taking levodopa (p < 0.0001). Increasing tHcy was associated with worse cognition in the PD cases, but not the other diagnostic groups. tHcy levels positively correlated with plasma Abeta levels even after adjustments for age and creatinine (p < 0.0001). Mean tHcy levels increased with age but did not discriminate diagnostic groups aside from significant elevation in patients with PD taking levodopa. The positive association between tHcy and plasma Abeta levels raises the possibility that these circulating factors could interact to affect AD risk and cognition in PD.